【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 16
1.2 List of Figures 22
2 Introduction 24
2.1 Catalyst 24
2.2 Related Reports 25
2.3 Upcoming Related Reports 25
3 Disease Overview 26
3.1 Etiology and Pathophysiology 26
3.1.1 Etiology 26
3.1.2 Pathophysiology and Histology 26
3.1.3 NSCLC Biomarkers 27
3.1.4 Quality of Life 28
3.2 Symptoms 29
4 Epidemiology 31
4.1 Risk Factors and Comorbidities 32
4.1.1 Smokers are more likely to have lung cancer than non-smokers 33
4.1.2 Long-term exposure to radon increases the risk of lung cancer 35
4.1.3 Family history of any cancer increases lung cancer risk 35
4.1.4 TB increases the risk of lung cancer and increases mortality risk 35
4.1.5 COPD is a comorbidity that reduces lung cancer survival 36
4.1.6 Lung cancer screening programs may not be beneficial 36
4.1.7 Stage at diagnosis significantly impacts the survival of lung cancer cases 37
4.2 Global Trends 38
4.2.1 US 41
4.2.2 France 46
4.2.3 Germany 47
4.2.4 Italy 49
4.2.5 Spain 51
4.2.6 UK 53
4.2.7 Japan 54
4.2.8 China 56
4.2.9 India 58
4.3 Forecast Methodology 60
4.3.1 Sources Used 62
4.3.2 Sources Not Used 67
4.3.3 Forecast Assumptions and Methods 67
4.4 Epidemiology Forecast (2012-2022) 70
4.4.1 Incident/Prevalent Cases of NSCLC 70
4.4.2 Age-Specific Incident Cases of NSCLC 72
4.4.3 Sex-Specific Incident Cases of NSCLC 73
4.4.4 Age-Standardized Incidence Rates of NSCLC 75
4.4.5 Segmentation of NSCLC Incident Cases 76
4.5 Discussion 84
4.5.1 Limitations of the Analysis 85
4.5.2 Strengths of the Analysis 86
5 Disease Management 87
5.1 Treatment Overview 87
5.1.1 Diagnosis 88
5.1.2 Clinical Staging 89
5.1.3 Screening and Early Detection 91
5.1.4 Localized Procedures and Therapies 92
5.1.5 Systemic Chemotherapy 93
5.1.6 Targeted Therapy 93
5.2 US 96
5.2.1 Diagnosis 96
5.2.2 Clinical Practice 96
5.3 France 98
5.3.1 Diagnosis 98
5.3.2 Clinical Practice 99
5.4 Germany 100
5.4.1 Diagnosis 100
5.4.2 Clinical Practice 101
5.5 Italy 103
5.5.1 Diagnosis 103
5.5.2 Clinical Practice 104
5.6 Spain 105
5.6.1 Diagnosis 105
5.6.2 Clinical Practice 105
5.7 UK 106
5.7.1 Diagnosis 106
5.7.2 Clinical Practice 107
5.8 Japan 108
5.8.1 Diagnosis 108
5.8.2 Clinical Practice 109
5.9 China 110
5.9.1 Diagnosis 110
5.9.2 Clinical Practice 111
5.10 India 112
5.10.1 Diagnosis 112
5.10.2 Clinical Practice 112
6 Competitive Assessment 115
6.1 Overview 115
6.2 Strategic Competitor Assessment 116
6.3 Product Profiles – Major Brands, Chemotherapies 118
6.3.1 Alimta (pemetrexed disodium) 118
6.3.2 Abraxane (nab-paclitaxel) 123
6.4 Product Profiles – Major Brands, Targeted Therapies 127
6.4.1 Avastin (bevacizumab) 127
6.4.2 Gilotrif (afatinib) 132
6.4.3 Iressa (gefitinib) 138
6.4.4 Tarceva (erlotinib hydrochloride) 143
6.4.5 Xalkori (crizotinib) 149
7 Opportunity and Unmet Need 156
7.1 Overview 156
7.2 Improved Overall Survival and Less Toxicity 157
7.3 Treatments for Patients with Acquired TKI Resistance 158
7.4 Better Treatment Options for Squamous Patients 158
7.5 Preventing Relapse or Recurrence 159
7.6 More Efficacious Second-Line Therapies 159
7.7 Increased Availability of Mutation Testing 160
7.8 More Cost-Effective Therapies 160
7.9 Unmet Needs Gap Analysis 161
8 Pipeline Assessment 165
8.1 Overview 165
8.2 Clinical Trial Mapping 165
8.2.1 Clinical Trials by Country 165
8.3 Clinical Trials by Phase and Trial Status 167
8.4 Promising Drugs in Clinical Development 168
8.4.1 Onartuzumab (MetMab) 172
8.4.2 Necitumumab (IMC-11F8) 177
8.4.3 Ramucirumab (IMC-1121B) 183
8.4.4 Custirsen (OGX-011) 188
8.4.5 Ganetespib (STA-9090) 194
8.4.6 Nintedanib (BIBF1120) 201
8.4.7 Dacomitinib (PF-00299804) 206
8.4.8 LDK378 (ceritinib) 211
8.4.9 Yervoy (ipilimumab) 217
8.4.10 Nivolumab (BMS936558) 222
8.4.11 MPDL3280A (RG7446) 230
8.4.12 GSK1572932A (MAGE-A3 Cancer Immunotherapy) 233
8.4.13 Halaven (eribulin mesylate) 237
9 Current and Future Players 243
9.1 Overview 243
9.2 Trends in Corporate Strategy 245
9.3 Company Profiles 246
9.3.1 Roche/Genentech 246
9.3.2 Pfizer 249
9.3.3 Bristol-Myers Squibb 251
9.3.4 Eli Lilly 254
9.3.5 Boehringer Ingelheim 257
9.3.6 Novartis 259
10 Market Outlook 261
10.1 Global Markets 261
10.1.1 Forecast 261
10.1.2 Drivers and Barriers – Global Issues 265
10.2 United States 269
10.2.1 Forecast 269
10.2.2 Key Events 273
10.2.3 Drivers and Barriers 274
10.3 France 277
10.3.1 Forecast 277
10.3.2 Key Events 281
10.3.3 Drivers and Barriers 282
10.4 Germany 284
10.4.1 Forecast 284
10.4.2 Key Events 288
10.4.3 Drivers and Barriers 289
10.5 Italy 291
10.5.1 Forecast 291
10.5.2 Key Events 295
10.5.3 Drivers and Barriers 295
10.6 Spain 297
10.6.1 Forecast 297
10.6.2 Key Events 300
10.6.3 Drivers and Barriers 301
10.7 United Kingdom 302
10.7.1 Forecast 302
10.7.2 Key Events 306
10.7.3 Drivers and Barriers 307
10.8 Japan 309
10.8.1 Forecast 309
10.8.2 Key Events 313
10.8.3 Drivers and Barriers 313
10.9 China 316
10.9.1 Forecast 316
10.9.2 Key Events 320
10.9.3 Drivers and Barriers 320
10.10 India 323
10.10.1 Forecast 323
10.10.2 Key Events 327
10.10.3 Drivers and Barriers 327
11 Appendix 329
11.1 Bibliography 329
11.2 Abbreviations 360
11.3 Methodology 365
11.4 Forecasting Methodology 365
11.4.1 Number of NSCLC Patients Currently Seeking Treatment 365
11.4.2 Percent Drug-Treated Patients 366
11.4.3 Drugs Included in Each Therapeutic Class 366
11.4.4 Launch and Patent Expiry Dates 367
11.4.5 General Pricing Assumptions 368
11.4.6 Individual Drug Assumptions 371
11.4.7 Generic Erosion 381
11.4.8 Pricing of Pipeline Agents 381
11.5 Physicians and Specialists Included in This Study 383
11.6 Survey of Prescribing Physicians 385
11.7 About the Authors 386
11.7.1 Authors 386
11.7.2 Epidemiologists 387
11.7.3 Global Head of Healthcare 388
11.8 About GlobalData 389
11.9 Disclaimer 389
【レポート販売概要】
■ タイトル：非小細胞肺がん：グローバル医薬品市場（～2022）■ 英文：PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
■ 発行日：2014年4月30日
■ 調査会社：GlobalData
■ 商品コード：GDHC002EPIDR
■ 調査対象地域：グローバル
- Source-to-Pay（S2P）アウトソーシングの世界市場：Source-to-Contract（S2C）アウトソーシング、Procure-to-Pay (P2P) アウトソーシングAbout global S2P outsourcing S2P is an effective strategy that delegates one or more business activities to external companies (suppliers) that then administer and manage the selected activity based on defined and measurable performance criteria. It helps clients operate efficiently, reduces time to market, and helps focus on core competencies. S2P leads to the successful creation of an economical …
- 肺動脈性肺高血圧症（PAH）の疫学的予測（～2024）EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024 Summary Pulmonary Arterial Hypertension (PAH) is a rare and severe condition characterized by vascular proliferation and remodeling of the small pulmonary arteries. This results in progressively increasing pulmonary vascular resistance, leading to an increase in pulmonary arterial pressure. The disease typically result …
- 医療産業向け発電装置の世界市場2016-2020About Generators Generators convert mechanical energy into electrical energy. The source of mechanical energy varies, from an internal combustion engine, a hand crank to compressed air to a reciprocating steam engine. An internal combustion engine uses either diesel, gasoline, propane gas, or natural gas to produce mechanical energy. This energy is then transformed into electrical energy with the …
- GRC（ガバナンス・リスク・コンプライアンス）プラットフォームの世界市場About GRC platform GRC platform is an umbrella term used to cover the approach of an organization toward the three areas: governance, risk, and compliance. Governance can be defined as the boundaries within which an organization should operate. It focuses on providing definitions for an organization's code of conduct to ensure compliance. Risk management consists of developing strategies for tackl …
- 血友病B(Hemophilia B)：世界の治験レビュー2014年下半期版Hemophilia B Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Hemophilia B Global Clinical Trials Review, H2, 2014" provides data on the Hemophilia B clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hemophilia B. It includes an overview of the trial numbers and their recruitment status as per the sit …
- 血液凝固分析装置の世界市場The global coagulation analyzers market is estimated to grow at a lower CAGR in developed countries; however, it is expected to witness high growth in emerging countries such as China, India, and Brazil in the next five years. Growth in the coagulation analyzers market is driven by factors such as increasing adoption of automated hemostasis instruments by diagnostics laboratories, development of h …
- 洋上風力発電の世界市場予測（～2022年）：風力タービン、土台、電気インフラ“The offshore wind market is projected to grow at a CAGR of 15.32% from 2017 to 2022” The offshore wind market is projected to reach USD 55.11 billion by 2022, at a CAGR of 15.32% from 2017 to 2022. The offshore wind market has been rapidly growing, especially in Europe as it contributed the European Union (EU) to meet its renewable energy targets for 2020. The global demand for electric power is …
- 世界の非小細胞性肺癌治療薬市場Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market Summary GBI Research, a leading business intelligence provider, has released its latest research report, “Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market” …
- 世界のトップ10高成長セラミックス市場The top 10 high growth ceramics market report provides a detailed analysis of the top 10 high growth avenues within the global ceramics market. It includes region-wise as well as segment-wise analysis of each market. The markets considered include electrical ceramics & electronics ceramics, ceramic coatings, and technical ceramics, among others. “Ceramic inks market is expected to grow at a CAGR o …
- 高機能顔料（HPP）の世界市場予測：有機、無機、ハイブリッド“The HPPs market is projected to register a CAGR of 4.3% during the forecast period.”The HPPs market size is projected to grow from USD 5.2 billion in 2019 to USD 6.4 billion by 2024, at a CAGR of 4.3% between 2019 and 2024. The growing number of commute vehicles in roadways, airways and waterways and growth in construction & infrastructure buildings is driving the growth of the HPPs industry. The …
- 神経痛（Neuralgia）治療のグローバル臨床試験動向（2014年H2）Neuralgia Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Neuralgia Global Clinical Trials Review, H2, 2014" provides data on the Neuralgia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuralgia. It includes an overview of the trial numbers and their recruitment status as per the site of trial c …
- 世界の企業向けソーシャルソフトウェア（ESS）市場About Social Software Social software is an IT offering from vendors, which enables organizations to enhance workforce productivity and foster innovation through the sharing of knowledge and ideas. Social software enables organizations to collaborate and integrate through blogs, wikis, conversations, forums, and communities. In short, social software provides a social networking experience to empl …
- スマートメーター用無線通信モジュール市場2013：市場分析と予測（～2020）Wireless Communication Modules for Smart Meters, 2013 Update - Market Analysis and Forecasts to 2020 Summary GlobalData's report “Wireless Communication Modules for Smart Meters, 2013 Update - Market Analysis and Forecasts to 2020” provides an analysis on the market developments in the global market for wireless communication modules used in smart meters. The key countries covered are the US, Cana …
- 土壌水分センサーの世界市場動向及び予測Soil moisture sensors are devices used to monitor the soil moisture component of the soil to improve the farm productivity and reduce the water consumption. This report has been segregated based on types, applications, and geographical regions. Soil moisture sensors are being widely used in areas, namely, agriculture, residential, landscaping and ground care, sports turf, weather forecasting, fore …
- 感染症サーベイランスソリューションの世界市場：ソフトウェア、サービス、エンドユーザー、地域別分析The global infection surveillance solutions market is estimated to reach USD 508.8 Million by 2021, at a CAGR of 14.1% during the forecast period. The market is primarily driven by the increasing incidence of healthcare-associated infections (HAIs), government policies for preventing HAIs, rising healthcare expenditures, and increasing number of surgeries. On the other hand, factors such as high c …
